SG Americas Securities
CLYM

SG Americas Securities’s Climb Bio CLYM Stock Holding History

SG Americas Securities’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,818
Closed -$17K – 3618
2025
Q2 		$17K Sell
13,818
-993
-7% -$1.24K ﹤0.01% 2838
2025
Q1 		$18K Sell
14,811
-16,177
-52% -$26.2K ﹤0.01% 3388
2024
Q4 		$56K Buy
30,988
+19,273
+165% +$69.7K ﹤0.01% 2890
2024
Q3 		$60K Buy
+11,715
New +$82.9K ﹤0.01% 3209

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SG Americas Securities's CLYM Position: Q3 2025 in Review

SG Americas Securities sold out of Climb Bio (CLYM) in Q3 2025, closing a stake of 13,818 shares — an estimated $17K sold.

SG Americas Securities first reported a position in CLYM in Q3 2024 and held it in 4 quarters. The position peaked at $60K in Q3 2024. 68 funds tracked by Wall St. Rank hold CLYM as of Q3 2025.

  • SG Americas Securities reported no remaining Climb Bio position as of Q3 2025 after selling out during the quarter.
  • SG Americas Securities sold 13,818 Climb Bio shares in Q3 2025, an estimated $17K.
  • SG Americas Securities first reported a position in Climb Bio in Q3 2024 and held it in 4 quarters.
  • SG Americas Securities's Climb Bio position peaked at $60K in Q3 2024.
  • 68 funds tracked by Wall St. Rank held Climb Bio as of Q3 2025.

Based on SG Americas Securities's 13F filing for Q3 2025, filed 23 Oct 2025.